689 related articles for article (PubMed ID: 8804877)
1. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
[TBL] [Abstract][Full Text] [Related]
2. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis.
Smith JL; Lewindon PJ; Hoskins AC; Pereira TN; Setchell KD; O'Connell NC; Shepherd RW; Ramm GA
Hepatology; 2004 Jun; 39(6):1673-82. PubMed ID: 15185309
[TBL] [Abstract][Full Text] [Related]
3. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
Lindblad A; Glaumann H; Strandvik B
Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
Colombo C; Crosignani A; Alicandro G; Zhang W; Biffi A; Motta V; Corti F; Setchell KDR
J Pediatr; 2016 Oct; 177():59-65.e1. PubMed ID: 27297203
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease.
Siano M; De Gregorio F; Boggia B; Sepe A; Ferri P; Buonpensiero P; Di Pasqua A; Raia V
Dig Liver Dis; 2010 Jun; 42(6):428-31. PubMed ID: 20034860
[TBL] [Abstract][Full Text] [Related]
7. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
Desmond CP; Wilson J; Bailey M; Clark D; Roberts SK
Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
[TBL] [Abstract][Full Text] [Related]
8. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
[TBL] [Abstract][Full Text] [Related]
9. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.
Mazzella G; Rizzo N; Azzaroli F; Simoni P; Bovicelli L; Miracolo A; Simonazzi G; Colecchia A; Nigro G; Mwangemi C; Festi D; Roda E
Hepatology; 2001 Mar; 33(3):504-8. PubMed ID: 11230728
[TBL] [Abstract][Full Text] [Related]
11. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis.
Rudolph G; Endele R; Senn M; Stiehl A
Hepatology; 1993 Jun; 17(6):1028-32. PubMed ID: 8514251
[TBL] [Abstract][Full Text] [Related]
12. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study.
Crosignani A; Battezzati PM; Setchell KD; Camisasca M; Bertolini E; Roda A; Zuin M; Podda M
Hepatology; 1991 Feb; 13(2):339-44. PubMed ID: 1671665
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy.
Kondrackiene J; Beuers U; Kupcinskas L
Gastroenterology; 2005 Sep; 129(3):894-901. PubMed ID: 16143129
[TBL] [Abstract][Full Text] [Related]
15. The importance of serum bile acid level analysis and treatment with ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a case series from central Europe.
Ambros-Rudolph CM; Glatz M; Trauner M; Kerl H; Müllegger RR
Arch Dermatol; 2007 Jun; 143(6):757-62. PubMed ID: 17576942
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid therapy in children with cholestatic liver disease.
Dinler G; Koçak N; Yüce A; Gürakan F; Ozen H
Turk J Pediatr; 1999; 41(1):91-8. PubMed ID: 10770681
[TBL] [Abstract][Full Text] [Related]
17. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C.
Takano S; Ito Y; Yokosuka O; Ohto M; Uchiumi K; Hirota K; Omata M
Hepatology; 1994 Sep; 20(3):558-64. PubMed ID: 7521313
[TBL] [Abstract][Full Text] [Related]
18. Quantification of individual serum bile acids in patients with liver diseases using high-performance liquid chromatography.
Okuda H; Obata H; Nakanishi T; Hisamitsu T; Matsubara K; Watanabe H
Hepatogastroenterology; 1984 Aug; 31(4):168-71. PubMed ID: 6479837
[TBL] [Abstract][Full Text] [Related]
19. Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy.
Brites D; Rodrigues CM; Oliveira N; Cardoso M; Graça LM
J Hepatol; 1998 Jan; 28(1):91-8. PubMed ID: 9537870
[TBL] [Abstract][Full Text] [Related]
20. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study.
Günsar C; Melek M; Karaca I; Sencan A; Mir E; Ortaç R; Canan O
Hepatogastroenterology; 2002; 49(44):497-500. PubMed ID: 11995481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
